P
ProHub
English 简体中文 繁體中文
Medium Market Entry Profitability

Diabetes Testing Meter

#Healthcare
ProHub Comment

This is a well-structured market entry case that tests candidate ability to build a financial model and recognize that market size constraints make profitability impossible. The case forces candidates to identify cannibalization risks and think creatively about alternative strategies when the primary market is unfeasible.

Estimated Time 26 minutes
Difficulty Medium
Source UCLA
10 / 100
Our client is a laboratory that provides diabetes testing services to hospitals in the UK. They have developed a self-diagnosis meter that patients can use to do testing on their own. They have hired us to determine if we should take this product to market.

Clarifying Information

  1. UK Population is ~60M
  2. 30% of people have diabetes
  3. 5% > 65 have diabetes
  4. 20% population is > 65
  5. No growth in % or population
  6. 4 competitors
  7. Market share 25%, 25%, 15%, 15%
  8. Client has 20% share
  9. Growth was 20% until two years ago
  10. Growth since is flat
  11. Fixed cost is $25M
  12. Marginal Cost is $20
  13. Per Unit Revenue is $25
  14. Patients could opt to use both methods
  15. Product could be promoted as a prevention device (low cost option for testing diabetes)
Mock Interview
Interviewer

Our client is a laboratory that provides diabetes testing services to hospitals in the UK. They have developed a self-diagnosis meter that patients can use to do testing on their own. They have hired us to determine if we should take this product to market.

You

Thanks. Before analyzing, I'd like to clarify a few key questions...

Interviewer

Good question. Let me provide some background information...

You

Based on this, I suggest analyzing from these dimensions...

AI Score
Structure Analysis Communication Business Sense Quantitative
Practicing...
Score coming soon
Practice this case with AI Mock Interview

A UK laboratory seeking to commercialize a diabetes self-testing meter must determine market viability. Analysis reveals break-even requires 5M units, but the addressable market is only 3M (20% of 15M diabetics), making UK launch economically unviable. The case highlights importance of market sizing discipline and considering cannibalization of existing hospital business.

Key Insights:

  1. Break-even analysis is foundational: Per-unit profit of $5 against $25M fixed costs requires 5M units, but market can only support 3M
  2. Population static with no growth eliminates the possibility of achieving profitability even with 100% market capture
  3. Cannibalization risk is critical: Home testing directly reduces hospital revenue for glucose testing services, undermining the client’s core business
  4. Geographic arbitrage presents solution: Markets like USA and Mexico with higher diabetes prevalence and no existing hospital testing business offer better economics
  5. Delivery channel considerations are essential in pharma: National insurance partnerships, hospital relationships, and doctor offices require different approaches than standard B2C distribution